We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset

By HospiMedica International staff writers
Posted on 23 Apr 2024

Atrial fibrillation, the most common type of cardiac arrhythmia worldwide, affected approximately 59 million people in 2019. More...

Characterized by an irregular and often rapid heart rate, atrial fibrillation occurs when the heart's upper chambers (atria) beat out of sync with the lower chambers (ventricles). Addressing arrhythmia can require aggressive interventions such as electrically shocking the heart back to a normal rhythm or surgically removing areas that generate faulty signals. Associated with increased risks of heart failure, dementia, and stroke, atrial fibrillation presents significant challenges to healthcare systems, emphasizing the importance of early detection and treatment. Traditional detection methods, relying on heart rate and electrocardiogram (ECG) data, typically identify atrial fibrillation just before its onset, offering no advanced warning.

Now, researchers from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg (Esch-sur-Alzette, Luxembourg) have achieved a breakthrough with the development of an advanced deep-learning model that can predict the onset of atrial fibrillation. Their model, named WARN (Warning of Atrial fibRillatioN), successfully provides early warnings about 30 minutes before atrial fibrillation begins, with approximately 80% accuracy.

This innovative model was trained and tested using 24-hour recordings from 350 patients, marking a significant improvement over previous prediction methods by offering a much earlier warning. The potential to integrate this technology into wearable devices could transform patient management, allowing for preemptive interventions that enhance outcomes. Notably, WARN stands out as the first method to offer a substantial lead time before the onset of atrial fibrillation, setting a new standard in arrhythmia prediction.

“Our work departs from this approach to a more prospective prediction model,” said Prof. Jorge Goncalves, head of the Systems Control group at the LCSB. “We used heart rate data to train a deep learning model that can recognize different phases – sinus rhythm, pre-atrial fibrillation and atrial fibrillation – and calculate a “probability of danger” that the patient will have an imminent episode.”

Related Links:
University of Luxembourg


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
New
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.